TGF-β has also been shown to suppress the expression of effector function on memory CD8+ T cells and reactive tumor-infiltrating lymphocytes, likely hindering the benefits of immunotherapy in cancer patients [174]. This evidence concerns the gene CD8A and neoplasm.